Clinical Summary
Clinical Summary: Antidepressants and Body Weight: A Comprehensive Review and Meta-Analysis
Weight gain can derail otherwise effective antidepressant treatment and add risk for diabetes mellitus, hypertension, and coronary heart disease. This review matters because antidepressants do not affect body weight uniformly, and the difference between short-term and long-term weight effects can directly shape drug selection for patients already at risk of obesity or weight-related medical illness.
Design
a systematic comprehensive and quantitative review of the literature
N
116 eligible reports
Population
adult patients
Duration
response within 4 to 12 weeks of treatment (acute treatment) and during longer periods (maintenance, > 4 months)
Key Findings
- The literature search yielded over 3,000 reports, and finally 116 studies were included in the analysis; of 116 selected trials, only 30 included a comparison between 1 or more antidepressant drugs with placebo.
- Estimates derived from randomized placebo-controlled studies did not significantly differ from those derived from observational nonplacebo studies for fluoxetine (P = .59), bupropion (P = .30), sertraline (P = .50), imipramine (P = .99), duloxetine (P = .15), paroxetine (P = .83), and amitriptyline (P = .98).
- Amitriptyline was significantly associated with weight gain over both acute and maintenance periods, while mirtazapine and nortriptyline were significantly associated with weight gain during acute treatment.
- Paroxetine was associated with a marginal weight loss during acute treatment but was associated with weight gain over the medium-long period; in particular, a significant weight gain was observed after 8 months of treatment.
- During acute treatment, citalopram, fluoxetine, sertraline, venlafaxine, duloxetine, bupropion, and moclobemide were associated with weight loss to various extents, but over the longer period only bupropion maintained a significant effect on weight.
Clinical Bottom Line
Antidepressants differ meaningfully in weight liability, and the time course matters: amitriptyline and mirtazapine are the clearest weight-gain concerns, paroxetine becomes more problematic with longer treatment, and bupropion is the only agent in this analysis with sustained weight-lowering effects beyond the acute phase.
Practice Implications
- When treating patients with major depressive disorder who are overweight or have obesity-related medical risk, factor expected treatment duration into antidepressant choice rather than relying on acute tolerability alone.
- Do not assume all selective serotonin reuptake inhibitors have the same weight profile: fluoxetine showed acute weight loss that did not persist, while paroxetine shifted to significant weight gain after 8 months of treatment.
- For patients in whom weight gain would meaningfully threaten adherence or metabolic health, bupropion stands out because it maintained a significant effect on weight beyond the acute period.
- Interpret smaller drug-specific maintenance findings cautiously because only 30 of 116 selected trials were placebo controlled, and the authors noted heterogeneity, possible publication bias, and limited data for some compounds.
